These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 21616560

  • 1. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [Abstract] [Full Text] [Related]

  • 2. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 3. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D.
    J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
    [Abstract] [Full Text] [Related]

  • 4. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Feb; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 6. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB.
    JAMA Dermatol; 2016 Jun 01; 152(6):661-9. PubMed ID: 26953848
    [Abstract] [Full Text] [Related]

  • 7. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC, Gerlier L, Brabant Y, Brown M.
    Clin Ther; 2008 Feb 01; 30(2):393-404. PubMed ID: 18343277
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Feb 01; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 10. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.
    J Am Acad Dermatol; 2010 May 01; 62(5):812-8. PubMed ID: 20219265
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 01; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 14. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Sep 01; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 15. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.
    Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH.
    J Rheumatol; 2008 Sep 01; 35(9):1729-36. PubMed ID: 18688916
    [Abstract] [Full Text] [Related]

  • 16. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
    Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.
    J Eur Acad Dermatol Venereol; 2014 Jun 01; 28(6):790-8. PubMed ID: 23679896
    [Abstract] [Full Text] [Related]

  • 17. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
    Louis E, Löfberg R, Reinisch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM.
    J Crohns Colitis; 2013 Feb 01; 7(1):34-43. PubMed ID: 22480772
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 01; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 19. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG.
    J Dermatolog Treat; 2011 Dec 01; 22(6):337-47. PubMed ID: 21034290
    [Abstract] [Full Text] [Related]

  • 20. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK, Hu A, Hillel AD.
    Laryngoscope; 2013 Nov 01; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.